Observational studyJournal of Korean medical science2025
Pulmonary Fibrosis in Critically Ill Patients With COVID-19: A Multi-Center Retrospective Cohort Study in Korea.
Observational study in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPulmonary fibrosis can persist long after recovery from coronavirus disease 2019 (COVID-19) infection, thereby reducing quality of life and lung function. We aimed to evaluate the frequency and risk factors for pulmonary fibrosis in patients with severe COVID-19 pneumonia requiring mechanical ventilation (MV), a high-risk group for developing pulmonary fibrosis.
methodsClinical data and chest computed tomography (CT) scans of patients with severe COVID-19 pneumonia requiring MV were retrospectively collected from nine hospitals in South Korea. Fibrotic-like changes on chest CT were visually assessed.
resultsWe included 125 patients with a mean age of 68.5 years, 60.8% men and 7.2% having underlying lung disease. Based on follow-up chest CT (the median interval, 38.0 days; interquartile range, 24.0-68.0 days), 94 (75.2%) patients exhibited fibrotic-like changes, with traction bronchiectasis and/or bronchiolectasis being the most common change (60.8%). Among all patients, 17.6% died during hospitalization and 71.2% experienced complications, including intubation-related airway injury (12.8%), ventilator-associated pneumonia (44.8%), lung injury (11.2%), and hemodynamic disturbance (33.4%). In-hospital mortality (16.1% vs. 18.1%) and complications (67.7% vs. 72.3%) were similar between patients with and without fibrotic-like changes. In multivariable logistic regression analysis, a higher daily steroid dose (odds ratio, 0.961; 95% confidence interval, 0.849-0.993;
conclusionOur study demonstrated that in patients with severe COVID-19 pneumonia requiring MV, chest CT revealed fibrotic-like changes in approximately three-quarters of patients. In addition, our results suggest that higher daily doses of steroids may be associated with a reduced risk of pulmonary fibrosis. Further research is needed to determine the appropriate steroid dose that may reduce the progression of pulmonary fibrosis and improve clinical outcomes.
trial registrationClinical Research Information Service Identifier: KCT0006312.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.